Treatment of SFA lesions with Drug-Eluting technologies
SUSTAINED RELEASE – SUPERIOR RESULTS
The Growing Evidence Base on Drug Eluting Technologies: A new Focus on Drug Eluting Stent
- Results of the IMPERIAL Randomized Controlled Trial of Eluvia vs Zilver PTX
- Drug Eluting Stent in Peripheral Artery Disease, Critical Limb Ischemia and Below The Knee indications
Boston Scientific is the only company investing in a complete portfolio of drug-eluting therapies, designed to revolutionize the field, as well as ground-breaking pre-clinical and clinical research that are helping define how to better use the technologies. Our commitment is to bring forward innovative therapies that can make a difference in the lives of patients, and our foundation of more than 15 years of design and development has established our clinical leadership.
DID YOU KNOW
WANT TO KNOW MORE?
Join our Drug-Eluting Technologies Community
Sign Up for Product Updates
Receive the latest news of Drug Eluting TechnologiesSIGN UP